Abstract
3590 Background: RAS status is the only biomarker to select patients with metastatic colorectal cancer (mCRC) for therapy with an epidermal growth factor receptor (EGFR) inhibitor. However, not all...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
